Trial · NCT04265261
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36 Measured in the Study Eye | Placebo | 7.89 | 95% Confidence Interval 2.72 to 20.8 | Percentage of participants | |
| Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36 Measured in the Study Eye | Vicasinabin 30 mg QD | 9.52 | 95% Confidence Interval 3.77 to 22.07 | Percentage of participants | |
| Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36 Measured in the Study Eye | Vicasinabin 200 mg QD | 5.71 | 95% Confidence Interval 1.58 to 18.61 | Percentage of participants | |
| Time-to-Event for Vision-Threatening DR in the Study Eye | Placebo | NA | 95% Confidence Interval 257.0 to NA | Days | |
| Time-to-Event for Vision-Threatening DR in the Study Eye | Vicasinabin 30 mg QD | 267.0 | 95% Confidence Interval 254.0 to NA | Days | |
| Time-to-Event for Vision-Threatening DR in the Study Eye | Vicasinabin 200 mg QD | NA | 95% Confidence Interval 260.0 to NA | Days | |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Placebo | New ASNV | 0 | 95% Confidence Interval 0.0 to 9.4 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 30 mg QD | New ASNV | 0 | 95% Confidence Interval 0.0 to 9.2 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 200 mg QD | New ASNV | 0 | 95% Confidence Interval 0.0 to 10.2 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Placebo | New PDR | 0 | 95% Confidence Interval 0.0 to 9.4 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 30 mg QD | New PDR | 6.3 | 95% Confidence Interval 1.6 to 18.2 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 200 mg QD | New PDR | 0 | 95% Confidence Interval 0.0 to 10.2 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Placebo | New DME | 0 | 95% Confidence Interval 0.0 to 9.4 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 30 mg QD | New DME | 4.2 | 95% Confidence Interval 0.7 to 15.4 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 200 mg QD | New DME | 0 | 95% Confidence Interval 0.0 to 10.2 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Placebo | Pre-existing DME requiring treatment | 4.3 | 95% Confidence Interval 0.7 to 15.7 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 30 mg QD | Pre-existing DME requiring treatment | 10.4 | 95% Confidence Interval 3.9 to 23.4 | Percentage of participants |
Incidence of New Anterior Segment Neovascularization (ASNV), New Proliferative Diabetic Retinopathy (PDR), New Diabetic Macular Edema (DME), and Pre-Existing DME Requiring Intervention in the Study Eye | Vicasinabin 200 mg QD | Pre-existing DME requiring treatment | 6.8 | 95% Confidence Interval 1.8 to 20.1 | Percentage of participants |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 36 | Placebo | 0.12 | Standard Error 0.747 | Number of letters | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 36 | Vicasinabin 30 mg QD | -0.45 | Standard Error 0.697 | Number of letters |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04265261/results